From Gut Health to Inflammation and Beyond: Why KPV, Larazotide, and VIP Are Peptide Rock Stars

Peptide therapy is often discussed as if every peptide does roughly the same thing. In reality, peptides can act very differently depending on the signals they carry and the cells that receive them. KPV, Larazotide, and Vasoactive Intestinal Peptide (VIP) are three great examples. All three have attracted attention for their potential roles in gut health, but that is only part of their story.

KPV is being studied for its ability to help regulate inflammation and immune activity, with research extending from the gastrointestinal tract to inflammatory skin conditions and tissue recovery. Larazotide takes a different approach by helping regulate the intestinal barrier and the tight junctions between intestinal cells, with some of its most important human research involving celiac disease. VIP has the broadest reach of the three, participating in communication between the nervous system, immune system, gastrointestinal tract, blood vessels, and lungs.

That is what makes these three peptides so interesting. They aren’t simply three different ways of treating the same problem. Each targets a different part of the body’s response to inflammation, injury, and barrier dysfunction, with potential applications that extend beyond where the research originally began. Let’s look at what makes KPV, Larazotide, and VIP worthy of the “peptide rock star” label while separating what the science supports from what is still being investigated.

KPV: When Inflammation Needs to Calm Down

Inflammation isn’t always bad. It’s one of the ways your body protects itself from injury and infection and starts the healing process. The problem is when inflammation becomes excessive or doesn’t settle down when it should. That’s where KPV gets interesting. This small peptide is being studied for its ability to help calm excessive inflammation without simply shutting down the body’s normal immune response.

The gut has become one of the major areas of KPV research. When the intestinal lining remains inflamed, it can become harder for that tissue to recover and maintain a healthy barrier. KPV appears to reduce some of the inflammatory signals involved in this process, potentially creating a better environment for the intestinal lining to heal and function normally.

But KPV isn’t just a gut peptide. Researchers have also explored its potential in skin inflammation, wound healing, tissue recovery, and antimicrobial activity. Much of this research is still in the laboratory or animal stage, so we don’t yet have the large human studies needed to call these proven benefits. The science is promising, but KPV remains an investigational peptide.

Larazotide: Helping Protect the Gut Barrier

Your intestinal lining has an important job. It needs to let nutrients into your body while helping keep bacteria, toxins, and other unwanted substances where they belong—inside the digestive tract. The cells lining the intestine are connected by structures called tight junctions, which work a little like adjustable gates. They help control what is allowed to pass between those cells and into the body.

Larazotide is being studied for its ability to help those tight junctions stay properly regulated. Much of the human research has focused on celiac disease, where gluten can trigger an immune reaction and disrupt the intestinal lining. Researchers have studied whether Larazotide can help maintain a stronger barrier and reduce some of the symptoms that occur after gluten exposure.

There is also growing interest in the connection between the gut barrier and inflammation elsewhere in the body. When tight junctions aren’t working properly, substances that would normally stay inside the intestine may have greater contact with the immune system, potentially contributing to inflammation. Researchers are still working to understand how important that connection may be. Larazotide remains investigational and is not FDA-approved, but its ability to target the tight junctions that control what crosses the intestinal lining makes this peptide particularly interesting.

VIP: A Peptide That Works Throughout the Body

Vasoactive Intestinal Peptide (VIP) is a naturally occurring peptide your body already makes, especially in the nervous system and digestive tract. Despite its name, VIP does much more than influence the intestines. It acts as a messenger between the nervous system, immune system, and different organs, helping regulate how these systems respond to changes in the body.

One of VIP’s important jobs is helping keep inflammation from becoming excessive while supporting normal immune function. In the gut, it also helps protect the intestinal lining, regulate tight junctions, control intestinal movement and secretion, and maintain blood flow. These combined effects have made VIP an important area of research for intestinal inflammation and conditions involving a disrupted gut barrier.

What really makes VIP stand out is how many other systems it influences. VIP can relax blood vessels and increase blood flow, relax the airways in the lungs, and influence communication within the nervous system. Researchers have studied VIP in pulmonary disease, inflammatory and autoimmune conditions, and neuroinflammation in addition to gastrointestinal disorders. Human research is still limited for many of these uses, and VIP is not FDA-approved for treating gut or inflammatory conditions. However, its ability to influence several interconnected systems makes VIP an intriguing area of ongoing research.

The Bottom Line

The growing interest in KPV, Larazotide, and VIP reflects an important part of peptide therapy: the goal isn’t simply to choose a peptide because it is popular. It is to understand what problem is being addressed and whether a particular peptide makes sense for that goal.

Peptide therapy also doesn’t replace conventional medical care or the need to determine why symptoms are occurring. Persistent abdominal pain, diarrhea, unexplained weight loss, bleeding, or other significant symptoms require appropriate medical evaluation. Celiac disease, inflammatory bowel disease, infections, medication effects, and other medical conditions need to be identified and treated appropriately.

KPV, Larazotide, and VIP remain investigational for the uses discussed in this article, and the strength of the research varies between them. As peptide research continues to develop, understanding both the potential and limitations of these therapies is just as important as understanding how they work.

Ready to Learn More About Peptide Therapy?

At Axios Health & Wellness, we offer individualized peptide consultations to help patients understand their options and determine whether peptide therapy may be appropriate for their health concerns and goals.

Call us at 720-899-9400 to schedule a consultation or visit AxiosHealthCO.com to learn more about our peptide therapy program.

About the Authors

This article was co-written by Jay Griffin, FNP-C, CRNFA, and Lacey Fisher, FNP-BC, PMHNP-BC.

Jay and Lacey are board-certified Family Nurse Practitioners and hormone optimization specialists at Axios Health & Wellness. Together, they bring decades of clinical experience in hormone replacement therapy, thyroid optimization, peptide therapy, medical weight loss, and regenerative medicine.

Their goal is to help patients better understand the science behind their health and make informed decisions through evidence-based, personalized care.

Jay Griffin, FNP-C, CRNFA

Board-Certified Family Nurse Practitioner
Hormone Optimization Specialist
Founder, Axios Health & Wellness

Lacey Fisher, FNP-BC, PMHNP-BC

Board-Certified Family Nurse Practitioner
Board-Certified Psychiatric Mental Health Nurse Practitioner
Hormone Optimization Specialist
Axios Health & Wellness

Frequently Asked Questions

Can KPV, Larazotide, and VIP be used together?

Potentially, but using multiple peptides should be based on the condition being addressed rather than simply combining therapies because they work differently. A clinician should consider the patient’s symptoms, medical history, medications, treatment goals, and available evidence before determining whether one peptide or a combination makes sense.

How are KPV, Larazotide, and VIP taken?

The route depends on the peptide and the reason it is being considered. These peptides may be compounded in different forms, including oral, injectable, or intranasal preparations. The route can matter because peptides are absorbed and processed differently depending on how they are administered.

How long does peptide therapy take to work?

There isn’t one timeline that applies to every peptide or every patient. Response can depend on the peptide being used, the condition being addressed, dose and route, and the individual’s health. Treatment should have a defined goal and a planned time to reassess whether it is actually helping.

Do you need laboratory testing before starting peptide therapy?

That depends on the peptide and the patient’s medical history. Baseline laboratory testing can help identify underlying health concerns, establish a starting point, and determine what should be monitored during treatment. Testing should be individualized rather than using the same laboratory panel for every peptide.

Are compounded peptides the same as FDA-approved medications?

No. A compounded medication is prepared for an individual patient by a compounding pharmacy and does not go through the same FDA approval process as a commercially manufactured FDA-approved drug. This distinction is especially important with investigational peptides, where the quality of the evidence, availability, and regulatory status can vary.